Nitric oxide-mediated regulation of transepithelial sodium and chloride transport in murine nasal epithelium

1999 ◽  
Vol 276 (3) ◽  
pp. L466-L473 ◽  
Author(s):  
Heather L. Elmer ◽  
Kristine G. Brady ◽  
Mitchell L. Drumm ◽  
Thomas J. Kelley
Keyword(s):  
Nitric Oxide ◽  
Chloride Transport ◽  
Chloride Secretion ◽  
Inos Expression ◽  
Potential Difference ◽  
Nasal Epithelium ◽  
Sodium Absorption ◽  
No Production ◽  
Transepithelial Potential ◽  
Transepithelial Potential Difference

Transepithelial ion transport is regulated by a variety of cellular factors. In light of recent evidence that nitric oxide (NO) production is decreased in cystic fibrosis airways, we examined the role of NO in regulating sodium and chloride transport in murine nasal epithelium. Acute intervention with the inducible NO synthase (iNOS)-selective inhibitor S-methylisothiourea resulted in an increase of amiloride-sensitive sodium absorption observed as a hyperpolarization of nasal transepithelial potential difference. Inhibition of iNOS expression with dexamethasone also hyperpolarized transepithelial potential difference, but only a portion of this increase proved to be amiloride sensitive. Chloride secretion was significantly inhibited in C57BL/6J mice by the addition of both S-methylisothiourea and dexamethasone. Mice lacking iNOS expression [NOS2(−/−)] also had a decreased chloride-secretory response compared with control mice. These data suggest that constitutive NO production likely plays some role in the downregulation of sodium absorption and leads to an increase in transepithelial chloride secretion.

Mechanism of distal tubular chloride transport in Amphiuma kidney

1982 ◽  
Vol 242 (4) ◽  
pp. F331-F339 ◽  
Author(s):  
H. Oberleithner ◽  
W. Guggino ◽  
G. Giebisch
Keyword(s):  
Cell Membrane ◽  
Cell Membranes ◽  
Chloride Transport ◽  
Potential Difference ◽  
Chloride Flux ◽  
Transepithelial Potential ◽  
Transepithelial Potential Difference ◽  
Net Flux ◽  
Chloride Activity ◽  
Electrochemical Equilibrium

To characterize the mechanism of chloride transport across individual cell membranes, experiments were carried out on early distal tubules in the doubly perfused Amphiuma kidney and net chloride flux, transepithelial and transmembrane cell potentials, and intracellular chloride activity measured. Net chloride flux was evaluated by a modified stationary microperfusion technique, and intracellular and intraluminal chloride activities by means of double-barreled liquid ion exchange microelectrodes. Control conditions were characterized by significant net volume and chloride reabsorption, a transepithelial potential difference of +9.0 +/- 0.5 mV (lumen positive), and cell chloride activities above electrochemical equilibrium across both luminal and peritubular cell membranes. Following luminal application of furosemide (5 X 10(-5) M) or perfusion with either a sodium- or chloride-free solution, net flux of chloride fell dramatically, the transepithelial potential difference was abolished, and cell chloride activity dropped sharply to approach electrochemical equilibrium. The decrease in transepithelial potential difference was fully accounted for by hyperpolarization of the basolateral cell membrane potential. These results are consistent with a furosemide-sensitive, electrically neutral sodium chloride cotransport mechanism across the luminal cell membrane.

scholarly journals Regulation of amiloride-sensitive sodium absorption in murine airway epithelium by C-type natriuretic peptide

1998 ◽  
Vol 274 (6) ◽  
pp. L990-L996 ◽  
Author(s):  
Thomas J. Kelley ◽  
Calvin U. Cotton ◽  
Mitchell L. Drumm
Keyword(s):  
Natriuretic Peptide ◽  
Guanylate Cyclase ◽  
Airway Epithelium ◽  
Phosphodiesterase Inhibitor ◽  
Airway Epithelial Cells ◽  
Potential Difference ◽  
Sodium Absorption ◽  
Transepithelial Potential ◽  
Transepithelial Potential Difference ◽  
Sodium Regulation

We have previously shown that C-type natriuretic peptide (CNP), a guanylate cyclase agonist, can stimulate cystic fibrosis transmembrane conductance regulator (CFTR)-mediated chloride secretion in murine airway epithelial cells via protein kinase (PK) A activation through the inhibition of cGMP-inhibited phosphodiesterases. In this paper, we show that CNP is also capable of reducing amiloride-sensitive sodium absorption in murine airway epithelium through a cGMP-dependent mechanism that is separate from the CFTR regulatory signaling pathway. Both murine tracheal and nasal tissues exhibit sensitivity to amiloride-sensitive sodium regulation by exogenously added CNP. CNP depolarized the nasal transepithelial potential difference by 6.3 ± 0.5 mV, whereas the cGMP-inhibited phosphodiesterase inhibitor milrinone actually hyperpolarized the nasal transepithelial potential difference by 2.0 ± 1.2 mV in mice homozygous for a CFTR stop mutation [CFTR(−/−)]. Inhibition of guanylate cyclase activity and PKG activity in normal mice resulted in an increase in amiloride-sensitive sodium absorption, suggesting that tonic regulation of amiloride-sensitive sodium absorption is in part due to basal cGMP levels and PKG activity.

Calcium secretion in canine tracheal mucosa

1985 ◽  
Vol 59 (4) ◽  
pp. 1191-1195 ◽  
Author(s):  
F. J. Al-Bazzaz ◽  
T. Jayaram
Keyword(s):  
Short Circuit ◽  
Short Circuit Current ◽  
Open Circuit ◽  
Potential Difference ◽  
Secretory Process ◽  
Metabolic Inhibitor ◽  
Tracheal Mucosa ◽  
Transepithelial Potential ◽  
Transepithelial Potential Difference

Calcium (Ca) affects many cellular functions of the respiratory tract mucosa and might alter the viscoelastic properties of mucus. To evaluate Ca homeostasis in a respiratory epithelium we investigated transport of Ca by the canine tracheal mucosa. Mucosal tissues were mounted in Ussing-type chambers and bathed with Krebs-Henseleit solution at 37 degrees C. Unidirectional fluxes of 45Ca were determined in tissues that were matched by conductance and short-circuit current (SCC). Under short-circuit conditions there was a significant net Ca secretion of 1.82 +/- 0.36 neq . cm-2 . h-1 (mean +/- SE). Under open-circuit conditions, where the spontaneous transepithelial potential difference could attract Ca toward the lumen, net Ca secretion increased significantly to 4.40 +/- 1.14 compared with 1.54 +/- 1.17 neq . cm-2 . h-1 when the preparation was short-circuited. Addition of a metabolic inhibitor, 2,4-dinitrophenol (2 mM in the mucosal bath), decreased tissue conductance and SCC and slightly decreased the unidirectional movement of Ca from submucosa to lumen. Submucosal epinephrine (10 microM) significantly enhanced Ca secretion by 2.0 +/- 0.63 neq . cm-2 . h-1. Submucosal ouabain (0.1 mM) failed to inhibit Ca secretion. The data suggest that canine tracheal mucosa secretes Ca; this secretory process is augmented by epinephrine or by the presence of a transepithelial potential difference as found under in vivo conditions.

scholarly journals Effects of Resveratrol on Inflammatory Biomarkers in Glaucomatous Human Trabecular Meshwork Cells

Nutrients ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 984 ◽  
Author(s):  
Selom Avotri ◽  
Danita Eatman ◽  
Karen Russell-Randall
Keyword(s):  
Nitric Oxide ◽  
Trabecular Meshwork ◽  
Interleukin 1 ◽  
Inos Expression ◽  
No Production ◽  
Enos Expression ◽  
Average Value ◽  
Beneficial Effects ◽  
Trabecular Meshwork Cells ◽  
Oxide Synthase

Purpose: Resveratrol (RSV), an antioxidant polyphenol, has demonstrated beneficial effects in various ocular diseases including glaucoma. Our study was designed to evaluate the effects of RSV on nitric oxide synthase (NOS) enzymes, nitric oxide (NO) and interleukin-1 alpha (IL-1 α), in human glaucomatous trabecular meshwork (TM) cells. Methods: Western blot was utilized to determine endothelial and inducible NOS (eNOS, iNOS) expression. The concentration-related effects of RSV on IL-1 α and NO levels were assessed using the respective ELISA kits. Results: Densitometry data showed concentration-related increases in eNOS, and reduction in iNOS expression at high RSV concentrations. RSV treatment (0.1, 1, 10 and 100 µM) resulted in increased NO levels (6 ± 0.7, 7 ± 0.8, 7.3 ± 0.7 and 9.5 ± 1 nM/mg protein, respectively). The average value obtained for control was 4.8 ± 0.6 nM/mg protein. Significant increases in IL-1α levels were observed with lower concentrations of RSV. However, at higher RSV concentrations (10–100 μM), IL-1 levels decreased. Conclusions: Resveratrol increased NO in glaucomatous TM cells, possibly by increasing eNOS expression. Thus, RSV-induced NO production supports the beneficial effects of this antioxidant in glaucoma. Furthermore, our results showing a reduction in iNOS, a contributor to oxidative stress expression, further support RSV’s antioxidant capabilities in vision.

Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB

2003 ◽  
Vol 285 (3) ◽  
pp. H1105-H1112 ◽  
Author(s):  
Bin Tian ◽  
Jian Liu ◽  
Peter Bitterman ◽  
Robert J. Bache
Keyword(s):  
Nitric Oxide ◽  
Angiotensin Ii ◽  
Cardiac Fibroblast ◽  
Inos Expression ◽  
No Production ◽  
Ang Ii ◽  
Phosphatidylinositol 3 Kinase ◽  
No Donor ◽  
At1 Antagonist ◽  
Phosphatidylinositol 3

Previously we found that interleukin-1β (IL-1β)-activated inducible nitric oxide (NO) synthase (iNOS) expression and that NO production can trigger cardiac fibroblast (CFb) apoptosis. Here, we provide evidence that angiotensin II (ANG II) significantly attenuated IL-1β-induced iNOS expression and NO production in CFbs while simultaneously decreasing apoptotic frequency. The anti-apoptotic effect of ANG II was abolished when cells were pretreated with the specific ANG II type 1 receptor (AT1) antagonist losartan, but not by the AT2 antagonist DP-123319. Furthermore, ANG II also protected CFbs from apoptosis induced by the NO donor diethylenetriamine NONOate and this effect was associated with phosphorylation of Akt/protein kinase B at Ser473. The effects of ANG II on Akt phosphorylation and NO donor-induced CFb apoptosis were abrogated when cells were preincubated with the specific phosphatidylinositol 3-kinase inhibitors wortmannin or LY-294002. These data demonstrate that ANG II protection of CFbs from IL-1β-induced apoptosis is associated with downregulation of iNOS expression and requires an intact phosphatidylinositol 3-kinase-Akt survival signal pathway. The findings suggest that ANG II and NO may play a role in regulating the cell population size by their countervailing influences on cardiac fibroblast viability.

scholarly journals Augmented inducible nitric oxide synthase expression and increased NO production reduce sepsis-induced lung injury and mortality in myeloperoxidase-null mice

2008 ◽  
Vol 295 (1) ◽  
pp. L96-L103 ◽  
Author(s):  
Viktor Brovkovych ◽  
Xiao-Pei Gao ◽  
Evan Ong ◽  
Svitlana Brovkovych ◽  
Marie-Luise Brennan ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Synthase ◽  
Inducible Nitric Oxide Synthase ◽  
Bacterial Colonization ◽  
Inos Expression ◽  
No Production ◽  
Bacterial Killing ◽  
E Coli ◽  
Oxide Synthase ◽  
Inducible Nitric Oxide

The myeloperoxidase (MPO)-hydrogen peroxide-halide system is an efficient oxygen-dependent antimicrobial component of polymorphonuclear leukocyte (PMN)-mediated host defense. However, MPO deficiency results in few clinical consequences indicating the activation of compensatory mechanisms. Here, we determined possible mechanisms protecting the host using MPO−/−mice challenged with live gram-negative bacterium Escherichia coli. We observed that MPO−/−mice unexpectedly had improved survival compared with wild-type (WT) mice within 5–12 h after intraperitoneal E. coli challenge. Lungs of MPO−/−mice also demonstrated lower bacterial colonization and markedly attenuated increases in microvascular permeability and edema formation after E. coli challenge compared with WT. However, PMN sequestration in lungs of both groups was similar. Basal inducible nitric oxide synthase (iNOS) expression was significantly elevated in lungs and PMNs of MPO−/−mice, and NO production was increased two- to sixfold compared with WT. Nitrotyrosine levels doubled in lungs of WT mice within 1 h after E. coli challenge but did not change in MPO−/−mice. Inhibition of iNOS in MPO−/−mice significantly increased lung edema and reduced their survival after E. coli challenge, but iNOS inhibitor had the opposite effect in WT mice. Thus augmented iNOS expression and NO production in MPO−/−mice compensate for the lack of HOCl-mediated bacterial killing, and the absence of MPO-derived oxidants mitigates E. coli sepsis-induced lung inflammation and injury.

scholarly journals Cholecystokinin Inhibits Inducible Nitric Oxide Synthase Expression by Lipopolysaccharide-Stimulated Peritoneal Macrophages

2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Rafael Simone Saia ◽  
Fabíola Leslie Mestriner ◽  
Giuliana Bertozi ◽  
Fernando Queiróz Cunha ◽  
Evelin Capellari Cárnio
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Synthase ◽  
Inducible Nitric Oxide Synthase ◽  
Peritoneal Macrophages ◽  
Inos Expression ◽  
No Production ◽  
Camp Content ◽  
Systemic Complications ◽  
Oxide Synthase ◽  
Inducible Nitric Oxide

Cholecystokinin (CCK) was first described as a gastrointestinal hormone. However, apart from its gastrointestinal effects, studies have described that CCK also plays immunoregulatory roles. Taking in account the involvement of inducible nitric oxide synthase- (iNOS-) derived NO in the sepsis context, the present study was undertaken to investigate the role of CCK on iNOS expression in LPS-activated peritoneal macrophages. Our results revealed that CCK reduces NO production and attenuates the iNOS mRNA expression and protein formation. Furthermore, CCK inhibited the nuclear factor- (NF-)κB pathway reducing IκBαdegradation and minor p65-dependent translocation to the nucleus. Moreover, CCK restored the intracellular cAMP content activating the protein kinase A (PKA) pathway, which resulted in a negative modulatory role on iNOS expression. In peritoneal macrophages, the CCK-1R expression, but not CCK-2R, was predominant and upregulated by LPS. The pharmacological studies confirmed that CCK-1R subtype is the major receptor responsible for the biological effects of CCK. These data suggest an anti-inflammatory role for the peptide CCK in modulating iNOS-derived NO synthesis, possibly controlling the macrophage activation through NF-κB, cAMP-PKA, and CCK-1R pathways. Based on these findings, CCK could be used as an adjuvant agent to modulate the inflammatory response and prevent systemic complications commonly found during sepsis.

Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4587-4587
Author(s):  
Ali Tabarroki ◽  
Daniel Lindner ◽  
Valeria Visconte ◽  
Nikolaos Papandantonakis ◽  
Jing Ai ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Bone Marrow ◽  
Growth Factor ◽  
Board Of Directors ◽  
Transforming Growth Factor ◽  
Myeloproliferative Neoplasms ◽  
Inos Expression ◽  
No Production ◽  
Advisory Committees ◽  
Extracellular Matrix Components

Abstract Bone marrow (BM) fibrosis is a key pathomorphologic feature of patients (pts) with primary myelofibrosis (PMF) and the fibrotic phases of essential thrombocythemia (post-ET MF) and polycythemia vera (post-PV MF). The degree of BM fibrosis appears to correlate with survival. Indeed worse survival has been associated with increased BM fibrosis. The BM stromal microenvironment is important in the pathogenesis of BM fibrosis. Cellular components (fibroblasts, macrophages, endothelial cells, adipocytes), structural fibrils (collagen, reticulin) and extracellular matrix components are all forming elements of the BM stroma. Increased stromal fibrosis has been linked to abnormalities in the number/ function of megakaryocytes and platelets in hematologic diseases. Several cytokines like Platelet Derived Growth Factor (PDGF) and Transforming Growth Factor-Beta (TGF-b) have been also linked to the pathophysiology of BM fibrosis. PDGF has been shown to increase fibroblast growth in megakaryocytes and platelets although increased PDGF did not correlate with increased production of either reticulin or collagenous fibrosis. Moreover, PMF pts have increased TGF-b levels in platelets, megakaryocytes, and monocytes. Nitric Oxide (NO) is a ubiquitous gas important in physiologic processes particularly vasodilatation. Dysregulation of NO levels has been implicated in pulmonary hypertension (PH), hemoglobinopathies, and cardiovascular diseases. In Peyronie’s disease, a localized fibrosis of the penile tunica albuginea, increased NO production by expression of iNOS decreases collagen deposition by neutralization of profibrotic reactive oxygen species and decreased myofibroblast formation. Aside from its role in maintaining normal vascular tone, NO also plays a role in fibroblast formation and collagen biosynthesis. We previously reported that ruxolitinib, a JAK1/2 inhibitor restores NO levels leading to improvement of PH in MF pts (Tabarroki et al., Leukemia 2014). We now hypothesize that plasma/serum NO level is a key regulator of BM fibrosis in MF and that ruxolitinib treatment (Tx) leads to improvement of BM fibrosis by NO modulation. Using a Sievers 280i NO analyzer we measured the plasma/serum NO level of a large cohort (n=75) of pts with myeloid and myeloproliferative neoplasms (MPN) [MDS, RARS/RCMD=8; MPN, ET=8, PV=8, MF=24, Mastocytosis=7; MDS/MPN, CMML=11, MDS/MPN-U, RARS-T=9]. Healthy subjects (n=10) were used as a control. MPN pts had low NO (nM) levels among the pts studied with the lowest level found in MF pts: MF=30.31±11.8, PV=39.0±16.1, ET=36±20.3, RARS=74.6±41.7 (P=.01), CMML=84.4±89.2 (P=.04), RCMD=163.4±103.8 (P<.001), RARS-T=131.1±99.8 (P<.001). In total, NO levels were lower in classic MPN (n=40, 35.3±16.6) compared to MDS (n=8, 119±62.8; P=.001) and MDS/MPN (n=20, 105±94.6; P=.008). When we looked at the correlation between NO levels and BM fibrosis grade we found that there is an inverse correlation between NO levels and worsening BM fibrosis grade from grade MF1 to MF3. NO levels in normal (n=10) vs MF1 (n=3) were 53.3 vs 39.1, P=.025; normal vs MF2 (n=7) were 53.3 vs 37, P=.021; normal vs MF3 (n=12) were 53.3 vs 34.4, P=.006. A total of 8 pts who were treated with ruxolitinib and had at least 1 pre and 1 post Tx (≥3 months from initiation of ruxolitinib) were tested for NO levels. Among the 8 pts, 4 pts who demonstrated improvement in BM scores had a trend towards improved NO levels after ruxolitinib Tx [NO pre vs post; pt #1: 6 vs 10.5; pt#2: 4.3 vs 6.4; pt#3 49.7 vs 52.1; pt#4 36 vs 41.3; P=.02] while 4 had worsening or had no change in BM fibrosis grade and had a minimal change or decline in the NO (pt#5: 18.4 vs 23, pt#6: 14.29 vs 12.1, pt#7: 32.7 vs 32.1, pt#8: 110.9 vs 40.4). One pt who had improvement in BM fibrosis grade after ruxolitinib Tx had increased iNOS expression by Western blotting (pt#1) while no iNOS expression (pt#5) was noted in the pt who did not have improvement in BM fibrosis. Of note, multi-analytic cytokines profile also showed an overall decrease in cytokines especially a 2.8 fold-decrease in IL8 levels post-Tx in the pt with improvement in BM fibrosis. In conclusion, NO is decreased in MPN particularly in MF and may be a key mediator of BM fibrosis in MF. Pharmacologic therapies such as JAK inhibitors may mediate improvement of BM fibrosis by modulation of NO levels in MF. Disclosures Tiu: Gilead: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Incyte : Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

Sign in / Sign up

Export Citation Format

Share Document